Bones of contention: Marrow-derived cells in myocardial regeneration
Bones of contention: Marrow-derived cells in myocardial regeneration
复制标题
DOI：
10.1016/j.yjmcc.2008.03.007
复制
发表时间：
2008-06-01
影响因子：
5
通讯作者：
Murry, Charles E.
中科院分区：
文献类型：
--
作者：
Sussman, Mark A.;Murry, Charles E.
自首次发表骨髓细胞再生梗死心肌的报道以来，已经过去了近7年。在随后的几年里，产生了数百项研究，从证实到反驳的发现都有，临床试验随后进行，以测试骨髓源性细胞群体用于心肌疾病临床治疗的安全性和有效性。在接下来的对话交流中，两位科学家以不同的观点权衡了追求骨髓干细胞治疗的利弊，并希望就再生医学和心脏的未来找到共识。结论是，从文献和会议上的敌意来看，这两个阵营的分歧可能并不像看起来那么大，而且有一天实现再生疗法的潜力确实是双方热情分享的愿景。(c) 2008爱思唯尔公司版权所有。
Almost 7 years have passed since the initial publication reporting that bone marrow cells regenerate infarcted myocardium. The subsequent years produced hundreds of investigations that ran the gamut of findings from validation to disproof Undeterred by the concurrent debate, clinical trials ensued to test the safety and efficacy of bone marrow-derived cell population for autologous therapy in clinical treatment of myocardial disease. In the following conversational exchange, two scientists with distinct perspectives weigh the pros and cons of pursuing bone marrow stem cell therapy and look toward finding a consensus of where the future lies for regenerative medicine and the heart. The conclusion is that the two camps may not be as far apart as it may seem from the rancor in literature and at meetings, and the potential of one day achieving regenerative therapy is indeed a vision that both parties enthusiastically share.. (c) 2008 Elsevier Inc. All rights reserved.